# A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

> **NCT04228783** · PHASE3 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 974 (actual)

## Conditions studied

- Ebola

## Interventions

- **BIOLOGICAL:** Ad26.ZEBOV
- **BIOLOGICAL:** MVA-BN-Filo
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04228783
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-18
- **Primary completion:** 2022-04-25
- **Final completion:** 2022-04-25
- **Target enrollment:** 974 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04228783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04228783, "A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04228783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*